The Experts below are selected from a list of 126633 Experts worldwide ranked by ideXlab platform
Toshihisa Osanai - One of the best experts on this subject based on the ideXlab platform.
-
Validity of measuring psoas Muscle Mass index for assessing sarcopenia in patients with gynecological cancer.
Japanese journal of clinical oncology, 2020Co-Authors: Ryutaro Yamada, Yukiharu Todo, Hiroyuki Kurosu, Kaoru Minowa, Tomohiko Tsuruta, Shinichiro Minobe, Hiroko Matsumiya, Hidenori Kato, Yoichi Mori, Toshihisa OsanaiAbstract:The current study evaluated the performance of psoas Muscle Mass measurement for detecting low skeletal Muscle Mass quantity. A sample of 82 consecutive patients with gynecological cancers was examined using computed tomography and dual energy X-ray absorptiometric scan before treatment. Skeletal Muscle Mass index was measured by dual energy X-ray absorptiometric scan and its cut-off value was set at 5.40 kg/m2 for detecting low skeletal Muscle Mass. Psoas Muscle Mass index was manually measured with cross-sectional computed tomography imaging at the level of L3 by six evaluators. Low skeletal Muscle Mass index was identified in 23 (28.0%) patients. Two-way analysis of variance confirmed a significant main effect of skeletal Muscle Mass index on mean psoas Muscle Mass index values (P < 0.0001). A receiver operating characteristic curve obtained from a total of 492 psoas Muscle Mass index data points gathered from six evaluators produced an area under the curve value of 0.697 (95% confidence interval 0.649-0.744) and a cut-off value of 3.52 cm2/m2, with sensitivity of 79.0% and specificity of 59.6%. Using the cut-off value, the kappa coefficient for evaluating diagnostic agreement between skeletal Muscle Mass index (low vs. normal) and psoas Muscle Mass index (low vs. normal) was 0.308 (95% confidence interval 0.225-0.392), suggesting poor agreement. Fleiss' kappa produced a coefficient of 0.418 (95% confidence interval 0.362-0.473), suggesting moderate agreement. Although relevance between skeletal Muscle Mass index and psoas Muscle Mass index was confirmed, intensity of relevance between them was weak. Psoas Muscle Mass index measurement should be subordinated to skeletal Muscle Mass index measurement for detection of low skeletal Muscle Mass. © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.
-
Validity of measuring psoas Muscle Mass index for assessing sarcopenia in patients with gynecological cancer.
Japanese journal of clinical oncology, 2020Co-Authors: Ryutaro Yamada, Yukiharu Todo, Hiroyuki Kurosu, Kaoru Minowa, Tomohiko Tsuruta, Shinichiro Minobe, Hiroko Matsumiya, Hidenori Kato, Yoichi Mori, Toshihisa OsanaiAbstract:OBJECTIVE The current study evaluated the performance of psoas Muscle Mass measurement for detecting low skeletal Muscle Mass quantity. METHODS A sample of 82 consecutive patients with gynecological cancers was examined using computed tomography and dual energy X-ray absorptiometric scan before treatment. Skeletal Muscle Mass index was measured by dual energy X-ray absorptiometric scan and its cut-off value was set at 5.40 kg/m2 for detecting low skeletal Muscle Mass. Psoas Muscle Mass index was manually measured with cross-sectional computed tomography imaging at the level of L3 by six evaluators. RESULTS Low skeletal Muscle Mass index was identified in 23 (28.0%) patients. Two-way analysis of variance confirmed a significant main effect of skeletal Muscle Mass index on mean psoas Muscle Mass index values (P
Seok Won Park - One of the best experts on this subject based on the ideXlab platform.
-
Type 2 diabetes is associated with low Muscle Mass in older adults.
Geriatrics & Gerontology International, 2014Co-Authors: Kyung-soo Kim, Kyung-sun Park, Moon-jong Kim, Soo-kyung Kim, Yong-wook Cho, Seok Won ParkAbstract:Aims Our aim was to clarify the association between type 2 diabetes and the risk of low Muscle Mass in older adults. Methods In the present study, 414 adults aged 65 years or older (144 patients with type 2 diabetes and 270 control participants) were included. Body composition was measured by dual-energy X-ray absorptiometry. Low Muscle Mass was defined as the appendicular skeletal Muscle Mass/height2 (ASM/Ht2) or appendicular skeletal Muscle Mass/weight (ASM/Wt) of
-
Type 2 diabetes is associated with low Muscle Mass in older adults.
Geriatrics & gerontology international, 2014Co-Authors: Kyung-soo Kim, Kyung-sun Park, Moon-jong Kim, Soo-kyung Kim, Yong-wook Cho, Seok Won ParkAbstract:Our aim was to clarify the association between type 2 diabetes and the risk of low Muscle Mass in older adults. In the present study, 414 adults aged 65 years or older (144 patients with type 2 diabetes and 270 control participants) were included. Body composition was measured by dual-energy X-ray absorptiometry. Low Muscle Mass was defined as the appendicular skeletal Muscle Mass/height(2) (ASM/Ht(2)) or appendicular skeletal Muscle Mass/weight (ASM/Wt) of <2 SD below the sex-specific normal mean of the young reference group, or <lower 20th percentile of total body skeletal Muscle Mass/weight (TSM/Wt) from control participants. Older men with type 2 diabetes showed significantly lower appendicular skeletal Muscle Mass than those without diabetes (19.5 ± 3.5 kg vs 21.0 ± 2.8 kg, P < 0.001). The prevalence of low Muscle Mass was consistently higher in older men with diabetes than those without diabetes defined by ASM/Ht(2) (57.6% vs 41.5%, P = 0.040), ASM/Wt (23.7% vs 12.3%, P = 0.046) and TSM/Wt (49.2% vs 20.0%, P < 0.001). In older women with diabetes, the prevalence of low Muscle Mass was higher than those without diabetes by ASM/Wt (25.9% vs 15.0%, P = 0.044) and TSM/Wt (32.9% vs 20.0%, P = 0.030), but not by ASM/Ht(2) (7.1% vs 8.6%, P = 0.685). The risk of low Muscle Mass was approximately two- to fourfold higher in older adults with type 2 diabetes, even after adjusting for age, body Mass index, current smoking and other risk factors. In Korean older adults, type 2 diabetes is associated with low Muscle Mass. © 2014 Japan Geriatrics Society.
Ryutaro Yamada - One of the best experts on this subject based on the ideXlab platform.
-
Validity of measuring psoas Muscle Mass index for assessing sarcopenia in patients with gynecological cancer.
Japanese journal of clinical oncology, 2020Co-Authors: Ryutaro Yamada, Yukiharu Todo, Hiroyuki Kurosu, Kaoru Minowa, Tomohiko Tsuruta, Shinichiro Minobe, Hiroko Matsumiya, Hidenori Kato, Yoichi Mori, Toshihisa OsanaiAbstract:The current study evaluated the performance of psoas Muscle Mass measurement for detecting low skeletal Muscle Mass quantity. A sample of 82 consecutive patients with gynecological cancers was examined using computed tomography and dual energy X-ray absorptiometric scan before treatment. Skeletal Muscle Mass index was measured by dual energy X-ray absorptiometric scan and its cut-off value was set at 5.40 kg/m2 for detecting low skeletal Muscle Mass. Psoas Muscle Mass index was manually measured with cross-sectional computed tomography imaging at the level of L3 by six evaluators. Low skeletal Muscle Mass index was identified in 23 (28.0%) patients. Two-way analysis of variance confirmed a significant main effect of skeletal Muscle Mass index on mean psoas Muscle Mass index values (P < 0.0001). A receiver operating characteristic curve obtained from a total of 492 psoas Muscle Mass index data points gathered from six evaluators produced an area under the curve value of 0.697 (95% confidence interval 0.649-0.744) and a cut-off value of 3.52 cm2/m2, with sensitivity of 79.0% and specificity of 59.6%. Using the cut-off value, the kappa coefficient for evaluating diagnostic agreement between skeletal Muscle Mass index (low vs. normal) and psoas Muscle Mass index (low vs. normal) was 0.308 (95% confidence interval 0.225-0.392), suggesting poor agreement. Fleiss' kappa produced a coefficient of 0.418 (95% confidence interval 0.362-0.473), suggesting moderate agreement. Although relevance between skeletal Muscle Mass index and psoas Muscle Mass index was confirmed, intensity of relevance between them was weak. Psoas Muscle Mass index measurement should be subordinated to skeletal Muscle Mass index measurement for detection of low skeletal Muscle Mass. © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.
-
Validity of measuring psoas Muscle Mass index for assessing sarcopenia in patients with gynecological cancer.
Japanese journal of clinical oncology, 2020Co-Authors: Ryutaro Yamada, Yukiharu Todo, Hiroyuki Kurosu, Kaoru Minowa, Tomohiko Tsuruta, Shinichiro Minobe, Hiroko Matsumiya, Hidenori Kato, Yoichi Mori, Toshihisa OsanaiAbstract:OBJECTIVE The current study evaluated the performance of psoas Muscle Mass measurement for detecting low skeletal Muscle Mass quantity. METHODS A sample of 82 consecutive patients with gynecological cancers was examined using computed tomography and dual energy X-ray absorptiometric scan before treatment. Skeletal Muscle Mass index was measured by dual energy X-ray absorptiometric scan and its cut-off value was set at 5.40 kg/m2 for detecting low skeletal Muscle Mass. Psoas Muscle Mass index was manually measured with cross-sectional computed tomography imaging at the level of L3 by six evaluators. RESULTS Low skeletal Muscle Mass index was identified in 23 (28.0%) patients. Two-way analysis of variance confirmed a significant main effect of skeletal Muscle Mass index on mean psoas Muscle Mass index values (P
Naoki Ishiguro - One of the best experts on this subject based on the ideXlab platform.
-
Use of alfacalcidol in osteoporotic patients with low Muscle Mass might increase Muscle Mass: an investigation using a patient database.
Geriatrics & Gerontology International, 2014Co-Authors: Sadayuki Ito, Atsushi Harada, Takehiro Kasai, Yoshihito Sakai, Marie Takemura, Yasumoto Matsui, Tetsuro Hida, Naoki IshiguroAbstract:Aim Sarcopenia causes a decline in physical performance and decreased quality of life. However, there is little evidence for effective treatments. Because of the similarities between osteoporosis and sarcopenia, alfacalcidol used for osteoporosis might be beneficial for low Muscle Mass. Therefore, we investigated the effect of alfacalcidol on Muscle Mass in patients with low Muscle Mass. Methods In this retrospective cohort analysis, patients from an osteoporosis database were divided into two groups: alfacalcidol-treated patients (vitamin D group; n = 156) and a control group without drug treatment (n = 233). Muscle Mass was evaluated in terms of the skeletal Muscle index (SMI; kg/m2) obtained from dual-energy X-ray absorptiometry measurements that were taken at the start and end of a 1-year period. Low Muscle Mass was determined using specific SMI cut-offs for Japanese individuals. Results Both the vitamin D group (mean age 73.7 ± 9.8 years) and the control group (mean age 72.3 ± 11.9 years) were primarily women (n = 141, 90.4%; n = 189, 81.1%, respectively). Low Muscle Mass was identified in 32.7% (n = 51) of the vitamin D group and 32.2% (n = 75) of the control group. The mean appendicular SMI in the vitamin D group did not change significantly over the 1-year period. The change was significant among the patients with low Muscle Mass (5.30 kg/m2 vs 5.49 kg/m2). The mean appendicular SMI in the control group decreased significantly over the 1-year period (6.09 kg/m2 vs 5.99 kg/m2). The change in the patients with low Muscle Mass was not significant. Conclusions The vitamin D group maintained Muscle Mass, and the SMI increased in patients with low Muscle Mass. Thus, the use of alfacalcidol might be effective in osteoporotic patients with low Muscle Mass. Geriatr Gerontol Int 2014; 14 (Suppl. 1): 122–128.
-
Use of alfacalcidol in osteoporotic patients with low Muscle Mass might increase Muscle Mass: an investigation using a patient database.
Geriatrics & gerontology international, 2014Co-Authors: Sadayuki Ito, Atsushi Harada, Takehiro Kasai, Yoshihito Sakai, Marie Takemura, Yasumoto Matsui, Tetsuro Hida, Naoki IshiguroAbstract:Sarcopenia causes a decline in physical performance and decreased quality of life. However, there is little evidence for effective treatments. Because of the similarities between osteoporosis and sarcopenia, alfacalcidol used for osteoporosis might be beneficial for low Muscle Mass. Therefore, we investigated the effect of alfacalcidol on Muscle Mass in patients with low Muscle Mass. In this retrospective cohort analysis, patients from an osteoporosis database were divided into two groups: alfacalcidol-treated patients (vitamin D group; n = 156) and a control group without drug treatment (n = 233). Muscle Mass was evaluated in terms of the skeletal Muscle index (SMI; kg/m(2)) obtained from dual-energy X-ray absorptiometry measurements that were taken at the start and end of a 1-year period. Low Muscle Mass was determined using specific SMI cut-offs for Japanese individuals. Both the vitamin D group (mean age 73.7 ± 9.8 years) and the control group (mean age 72.3 ± 11.9 years) were primarily women (n = 141, 90.4%; n = 189, 81.1%, respectively). Low Muscle Mass was identified in 32.7% (n = 51) of the vitamin D group and 32.2% (n = 75) of the control group. The mean appendicular SMI in the vitamin D group did not change significantly over the 1-year period. The change was significant among the patients with low Muscle Mass (5.30 kg/m(2) vs 5.49 kg/m(2)). The mean appendicular SMI in the control group decreased significantly over the 1-year period (6.09 kg/m(2) vs 5.99 kg/m(2)). The change in the patients with low Muscle Mass was not significant. The vitamin D group maintained Muscle Mass, and the SMI increased in patients with low Muscle Mass. Thus, the use of alfacalcidol might be effective in osteoporotic patients with low Muscle Mass. © 2014 Japan Geriatrics Society.
Hidenori Kato - One of the best experts on this subject based on the ideXlab platform.
-
Validity of measuring psoas Muscle Mass index for assessing sarcopenia in patients with gynecological cancer.
Japanese journal of clinical oncology, 2020Co-Authors: Ryutaro Yamada, Yukiharu Todo, Hiroyuki Kurosu, Kaoru Minowa, Tomohiko Tsuruta, Shinichiro Minobe, Hiroko Matsumiya, Hidenori Kato, Yoichi Mori, Toshihisa OsanaiAbstract:The current study evaluated the performance of psoas Muscle Mass measurement for detecting low skeletal Muscle Mass quantity. A sample of 82 consecutive patients with gynecological cancers was examined using computed tomography and dual energy X-ray absorptiometric scan before treatment. Skeletal Muscle Mass index was measured by dual energy X-ray absorptiometric scan and its cut-off value was set at 5.40 kg/m2 for detecting low skeletal Muscle Mass. Psoas Muscle Mass index was manually measured with cross-sectional computed tomography imaging at the level of L3 by six evaluators. Low skeletal Muscle Mass index was identified in 23 (28.0%) patients. Two-way analysis of variance confirmed a significant main effect of skeletal Muscle Mass index on mean psoas Muscle Mass index values (P < 0.0001). A receiver operating characteristic curve obtained from a total of 492 psoas Muscle Mass index data points gathered from six evaluators produced an area under the curve value of 0.697 (95% confidence interval 0.649-0.744) and a cut-off value of 3.52 cm2/m2, with sensitivity of 79.0% and specificity of 59.6%. Using the cut-off value, the kappa coefficient for evaluating diagnostic agreement between skeletal Muscle Mass index (low vs. normal) and psoas Muscle Mass index (low vs. normal) was 0.308 (95% confidence interval 0.225-0.392), suggesting poor agreement. Fleiss' kappa produced a coefficient of 0.418 (95% confidence interval 0.362-0.473), suggesting moderate agreement. Although relevance between skeletal Muscle Mass index and psoas Muscle Mass index was confirmed, intensity of relevance between them was weak. Psoas Muscle Mass index measurement should be subordinated to skeletal Muscle Mass index measurement for detection of low skeletal Muscle Mass. © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.
-
Validity of measuring psoas Muscle Mass index for assessing sarcopenia in patients with gynecological cancer.
Japanese journal of clinical oncology, 2020Co-Authors: Ryutaro Yamada, Yukiharu Todo, Hiroyuki Kurosu, Kaoru Minowa, Tomohiko Tsuruta, Shinichiro Minobe, Hiroko Matsumiya, Hidenori Kato, Yoichi Mori, Toshihisa OsanaiAbstract:OBJECTIVE The current study evaluated the performance of psoas Muscle Mass measurement for detecting low skeletal Muscle Mass quantity. METHODS A sample of 82 consecutive patients with gynecological cancers was examined using computed tomography and dual energy X-ray absorptiometric scan before treatment. Skeletal Muscle Mass index was measured by dual energy X-ray absorptiometric scan and its cut-off value was set at 5.40 kg/m2 for detecting low skeletal Muscle Mass. Psoas Muscle Mass index was manually measured with cross-sectional computed tomography imaging at the level of L3 by six evaluators. RESULTS Low skeletal Muscle Mass index was identified in 23 (28.0%) patients. Two-way analysis of variance confirmed a significant main effect of skeletal Muscle Mass index on mean psoas Muscle Mass index values (P
